INTECH Investment Management
TRDA icon

INTECH Investment Management’s Entrada Therapeutics TRDA Stock Holding History

INTECH Investment Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,929
Closed -$123K – 2352
2025
Q4 		$123K Sell
11,929
-1,914
-14% -$16.1K ﹤0.01% 2110
2025
Q3 		$80.3K Sell
13,843
-3,859
-22% -$22.6K ﹤0.01% 2310
2025
Q2 		$119K Buy
17,702
+2,397
+16% +$19.3K ﹤0.01% 2253
2025
Q1 		$138K Buy
+15,305
New +$191K ﹤0.01% 2222

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

INTECH Investment Management's TRDA Position: Q1 2026 in Review

INTECH Investment Management sold out of Entrada Therapeutics (TRDA) in Q1 2026, closing a stake of 11,929 shares — an estimated $123K sold.

INTECH Investment Management first reported a position in TRDA in Q1 2025 and held it in 4 quarters. The position peaked at $138K in Q1 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • INTECH Investment Management reported no remaining Entrada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • INTECH Investment Management sold 11,929 Entrada Therapeutics shares in Q1 2026, an estimated $123K.
  • INTECH Investment Management first reported a position in Entrada Therapeutics in Q1 2025 and held it in 4 quarters.
  • INTECH Investment Management's Entrada Therapeutics position peaked at $138K in Q1 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.